Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…
Search results for: hospital
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease
Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…
Stay the Course: How to Maintain Remission in Vasculitis
MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…
ACR on Air: New Rheumatology Podcast Introduced
A new podcast from the ACR provides in-depth discussions about newly published science, regulatory updates, advocacy and volunteer opportunities for the rheumatology community…
FDA Approves Upadacitinib for RA
Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…
Intensive, Personalized Learning
During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…
Filgotinib Promising for RA
Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…
Shingles Vaccine Not the Only Immunization Linked with Gout Flare
NEW YORK (Reuters Health)—The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say. “Our findings are novel because for the first time, we have identified a trigger for gout flares that presumably acts through [an inflammatory] pathway,…
Improved Pregnancy Outcomes for Women with SLE
Recent research indicates that previous concerns about mortality associated with pregnancy in women with SLE may no longer be applicable. In the study, researchers found a significant decline in the in-hospital maternal mortality rate of women with SLE and a decrease in their length of non-delivery related hospitalization over the past two decades…
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 320
- Next Page »